Villages | Variables | Periods of survey | ||||
---|---|---|---|---|---|---|
 |  | October 2008 | January 2009 | June 2009 | October 2009 | January 2010 |
Agniam (n=41) | An. gambiae Bites/human/night | 8.37 | 0 | 1.62 | 12.5 | 0.5 |
 | An. gambiae Females/Room/night | 41 | 0.2 | 7.6 | 28.4 | 4.4 |
 | % P. falciparum prevalence (95% CI)a | 12.20 (2.18 ; 22.22) | 19.50 (7.38 ; 31.64) | 4.90 (-1.77 ; 11.47) | 0.00 | 2.40 (-2.28 ; 7.16) |
 | % of immune responders (95% CI)b | 80.49 (68.36 ; 92.62) | 34.15 (19.63 ; 48.67) | 29.27 (15.34 ; 43.2) | 82.92 (71.41 ; 94.45) | 24.40 (11.25 ; 37.53) |
Niandane (n=71) | An. gambiae Bites/human/night | 13.87 | 0.62 | 1.5 | 11.12 | 0 |
An. gambiae Females/Room/night | 11.6 | 0.6 | 1.4 | 9.4 | 0 | |
% P. falciparum prevalence (95% CI) | 21.10 (11.63 ; 30.63) | 24.00 (14.01 ; 33.87) | 4.20 (-0.45 ; 8.91) | 4.20 (-0.45 ; 8.91) | 0.00 | |
% of immune responders (95% CI) | 54.93 (43.36 ; 66.5) | 21.12 (11.63 ; 30.63) | 18.30 (9.30 ; 27.30) | 33.80 (22.8 ; 44.8) | 14.08 (5.99 ; 22.17) | |
Pendao (n=37) | An. gambiae Bites/human/night | 9.25 | 0.87 | 3.5 | 0.87 | 0.62 |
An. gambiae Females/Room/night | 20.4 | 0.6 | 7.6 | 4.8 | 0.2 | |
% P. falciparum prevalence (95% CI) | 5.40 (-1.88 ; 12.7) | 16.20 (4.34 ; 28.1) | 2.70 (-2.52 ; 7.92) | 0.00 | 0.00 | |
% of immune responders (95% CI) | 37.84 (22.21 ; 53.47) | 24.32 (10.5 ; 38.14) | 10.81 (0.8 ; 20.82) | 32.43 (17.37 ; 47.51) | 8.11 (-0.69 ; 16.91) | |
Guede (n=41) | An. gambiae Bites/human/night | 7.12 | 0 | 0.25 | 9.37 | 1.75 |
An. gambiae Females/Room/night | 9.8 | 0 | 3 | 7.8 | 3.6 | |
% P. falciparum prevalence (95% CI) | 9.75 (0.68 ; 18.84) | 31.70 (17.47 ; 45.95) | 7.30 (-0.65 ; 15.29) | 0.00 | 4.90 (-1.71 ; 11.47) | |
% of immune responders (95% CI) | 39.02 (24.09 ; 53.95) | 7.32 (-0.65 ; 15.29) | 21.95 (9.28 ; 34.62) | 43.90 (28.71 ; 59.09) | 12.19 (2.18 ; 22.22) | |
Fanaye (n=75) | An. gambiae Bites/human/night | 2.75 | 0 | 0.75 | 3.87 | 0.37 |
 | An. gambiae Females/Room/night | 7.8 | 1.4 | 1.2 | 7.4 | 1.2 |
 | % P. falciparum prevalence (95% CI) | 16.00 (8.76 ; 25.9) | 18.70 (9.85 ; 27.49) | 2.70 (-0.98 ; 6.32) | 1.30 (-1.26 ; 3.92) | 0.00 |
 | % of immune responders (95% CI) | 9.33 (2.75 ; 15.91) | 0.00 | 1.33 (-1.26 ; 3.92) | 0.00 | 1.33 (-1.26 ; 3.92) |